Combined actions of ivabradine and ranolazine reduce ventricular rate during atrial fibrillation

Journal of Cardiovascular Electrophysiology

Volumn 26, Issue 3, 2015, Pages 329-335

  Verrier, Richard L ^a,b   Silva, Ana F G ^a,c   Bonatti, Rodolfo ^a,c   Batatinha, Julio A P ^a,c   Nearing, Bruce D ^a,b   Liu, Gongxin ^d   Rajamani, Sridharan ^d   Zeng, Dewan ^d   Belardinelli, Luiz ^d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d GILEAD SCIENCES   (United States)

Author keywords

atrial fibrillation; atrioventricular node; dominant frequency; funny current; sodium current; ventricular rate

Indexed keywords

IVABRADINE; RANOLAZINE; BENZAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT;

AH INTERVAL; ARTICLE; CARDIOVASCULAR PARAMETERS; CONTINUOUS INFUSION; DRUG SAFETY; HEART ATRIOVENTRICULAR NODE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE CONTRACTILITY; HEART PACING; HEART RATE; HEMODYNAMIC PARAMETERS; HIS VENTRICULAR INTERVAL; LOW DRUG DOSE; MEAN ARTERIAL PRESSURE; POTASSIUM CURRENT; PR INTERVAL; PRIORITY JOURNAL; QT INTERVAL; SINUS NODE CONDUCTION VELOCITY; SINUS RHYTHM; SODIUM CURRENT; ANIMAL; ATRIAL FIBRILLATION; DRUG COMBINATION; DRUG EFFECTS; GUINEA PIG; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; PIG;

ANIMALS; ATRIAL FIBRILLATION; BENZAZEPINES; CARDIOVASCULAR AGENTS; DRUG THERAPY, COMBINATION; GUINEA PIGS; HEART RATE; MALE; RANOLAZINE; SWINE;

EID: 84924597326     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/jce.12569     Document Type: Article

References (24)

1. Munk AA, Adjemian RA, Zhao J, Ogbaghebriel A, Shrier A,: Electrophysiological properties of morphologically distinct cells isolated from the rabbit atrioventricular node. J Physiol 1996; 493: 801-818.
2. Shi W, Wymore R, Yu H, Wu J, Wymore RT, Pan Z, Robinson RB, Dixon JE, McKinnon D, Cohen IS,: Distribution and prevalence of hyperpolarization-activated cation channel (HCN) mRNA expression in cardiac tissues. Circ Res 1999; 85: e1-e6.
3. Dobrzynski H, Nikolski VP, Sambelashvili AT, Greener ID, Yamamoto M, Boyett MR, Efimov IR,: Site of origin and molecular substrate of atrioventricular junctional rhythm in the rabbit heart. Circ Res 2003; 93: 1102-1110.
4. Di Francesco D,: The role of the funny current in pacemaker activity. Circ Res 2010; 106: 434-446.
5. Chiamvimonvat V, Newman D, Tang A, Green M, Mitchell J, Wulffhart Z, Doran P,: A double-blind placebo-controlled evaluation of the human electrophysiologic effects of zatebradine, a sinus node inhibitor. J Cardiovasc Pharmacol 1998; 32: 516-520.
6. f in the atrioventricular node as a mechanism for dronedarone's reduction in ventricular rate during atrial fibrillation. Heart Rhythm 2013; 10: 1692-1697.
7. Kumar K, Nearing BD, Carvas M, Nascimento BCG, Acar M, Belardinelli L, Verrier RL,: Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. J Cardiovasc Electrophysiol 2009; 20: 796-802.
8. f inhibition in the atrioventricular node by ivabradine causes rate-dependent slowing of conduction and reduces ventricular rate during atrial fibrillation. Heart Rhythm 2014; 11: 2288-2296.
9. Reffelmann T, Kloner RA,: Ranolazine: An anti-anginal drug with further therapeutic potential. Expert Rev Cardiovasc Ther 2010; 8: 319-329.
10. Verrier RL, Pagotto VPF, Kanas AF, Sobrado MF, Nearing BD, Zeng D, Belardinelli L,: Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia. Heart Rhythm 2013; 10: 121-127.
11. Camm AJ, Lau CP,: Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R D 2003; 4: 83-89.
12. f inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 2003; 100: 149-155.
13. f inhibition with ivabradine: Electrophysiological effects and safety. Drug Safety 2008; 31: 95-107.
14. Everett TH, Kok LC, Vaughn RH, Moorman JR, Haines DE,: Frequency domain algorithm for quantifying atrial fibrillation organization to increase defibrillation efficacy. IEEE Trans Biomed Eng 2001; 48: 969-978.
15. f inhibitor, in the anesthetized dog heart. J Cardiovasc Pharmacol 1995; 26: 957-964.
16. Baruscotti M, Barbuti A, Bucchi A,: The cardiac pacemaker current. J Mol Cell Cardiol 2010; 48: 55-64.
17. Hancox JC, Levi AJ, Lee CO, Heap P,: A method for isolating rabbit atrioventricular node myocytes which retain normal morphology and function. Am J Physiol 1993; 265: H755-H766.
18. Yuill KH, Hancox JC,: Characteristics of single cells isolated from the atrioventricular node of the adult guinea-pig heart. Pflugers Arch 2002; 445: 311-320.
19. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C,: Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation. Differences in sodium channel inactivation between atria and ventricles and the role of ranolazine-selective sodium channel block as a novel strategy for the management of AF. Circulation 2007; 116: 1449-1457.
20. Chou CC, Nguyen BL, Tan AY, Chang PC, Lee HL, Lin FC, Yeh S-J, Fishbein MC, Lin S-F, Wu D, Wen M-S, Chen P-S,: Intracellular calcium dynamics and acetylcholine-induced triggered activity in the pulmonary veins of dogs with pacing-induced heart failure. Heart Rhythm 2008; 5: 1170-1177.
21. Antzelevitch C, Burashnikov A, Sicouri S, Belardinelli L,: Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm 2011; 8: 1281-1290.
22. Sicouri S, Glass A, Belardinelli L, Antzelevitch C,: Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm 2008; 5: 1019-1026.
23. Servier. Procorlan: Summary of Product Characteristics. http://www.servier.com/sites/default/files/Summary%20of%20Product%20Characteristics%20Procoralan%209-2-2012.pdf
24. f in the human atrium. J Cardiovasc Electrophysiol 2013; 24: 1391-1400.